Related Experiment Video
Updated: Jan 21, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application
1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, First Affiliated Hospital of South China University of Technology, Guangzhou 510080, PR China.
Abstract:
Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI) that irreversibly binds to and inhibits EGFR/Her1, Her2 and Her4 subtypes with an efficacy comparable to other TKIs. In the ARCHER 1050 trial, progression-free survival was improved by dacomitinib compared with gefitinib, supporting dacomitinib as a first-line treatment option for advanced non-small-cell lung cancer with sensitive EGFR mutation. Regarding to the higher adverse events rate, dose reductions did not reduce the efficacy of dacomitinib and could effectively decreased the incidence and severity of adverse events. Considering the evolving landscape of EGFR-mutant non-small-cell lung cancer, future head to head comparison between dacomitinib and osimertinib could provide key information to determine the optimal TKI treatment schedule.
Insights
Dacomitinib improves progression-free survival in advanced non-small-cell lung cancer with EGFR mutations. Dose reductions manage side effects without compromising efficacy, supporting its role as a first-line treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Dacomitinib is a second-generation EGFR tyrosine kinase inhibitor (TKI). It irreversibly inhibits EGFR/Her1, Her2, and Her4 subtypes.
- Its efficacy is comparable to other TKIs in treating non-small-cell lung cancer (NSCLC).
Purpose of the Study:
- To evaluate dacomitinib as a first-line treatment for advanced NSCLC with EGFR mutations.
- To assess the impact of dose reductions on dacomitinib's efficacy and adverse events.
Main Methods:
- The ARCHER 1050 trial compared dacomitinib with gefitinib in advanced NSCLC patients.
- Adverse events and the effect of dose reductions on efficacy were analyzed.
Main Results:
- Dacomitinib demonstrated improved progression-free survival compared to gefitinib.
- Dose reductions effectively decreased the incidence and severity of adverse events without reducing efficacy.
Conclusions:
- Dacomitinib is a viable first-line treatment option for advanced NSCLC with EGFR mutations.
- Dose adjustments can mitigate toxicity, enhancing patient tolerability.
- Future comparisons with osimertinib are needed to optimize TKI treatment strategies.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Local Anesthetics: Clinical Application as Spinal Anesthesia
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...